You are here

Home » Content

Otozomal Dominant Polikistik Böbre k Hastalığında Hipertansiyon ve Kardiyovasküler Sorunlar

Hypertension and Cardiovascular Problems in Autosomal Dominant Polycystic Kidney Disease

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Otozomal dominan t polikistik böbrek hastalığı i (ODPBH), her iki böbrekte kistik değişiklikler gös¬teren sistemik ve kalıtsal bir hastalıktır. Otozomal dominant polikistik böbrek hastalığı, en sık görülen kalıtsal böbrek hastalığıdır ve son dönem böbrek i yetersizliği (SDBY) olgularının %5-10'undan sorum- i ludur (1). Hipertansiyon, bu hastalıkta sık karşılaşı- j lan bir bulgu olup hastaların morbidİte ve mortalite- j sinde önemli bir rol oynar (2). Hipertansiyon, hasta- j ların yaklaşık %60'ında böbrek fonksiyonları bozul- i madan önce ortaya çıkar (2,3). Hipertansiyonu olan \ polikistik böbrek hastalarında böbrek fonksiyonları j daha hızlı bozulur (4). Ayrıca, hipertansiyon, bu | hastaların en sık ölüm nedeni olan kardiyovasküler | hastalıklar için önemli bir risk faktörüdür (5).
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_22-26.pdf
  • 1
22-26
  • Turkish

REFERENCES

References: 

1. Eick-Brosnahan GM, Betler T. Schrier KW. Polycystic kidney disease. İn: Schrier KW led). Diseases of the Kidney and Urinary Tract (7tli ed). Uppineott, Williams & Wilkins, Philadelphia 21X11, pp 547-588,
2. Killer T, Schrier KW. Hypertension in autosomal-dominani polycystic kidney disease: Karly incurrence and unique aspects. J Am Sac Nephrol 2001; 12 194-200.
5, Gahow PA. Chapman AB, Johnson AM et ai. Renal structure and hypertension in auiosuni.il dominant polycystic kidney disca.se. Kidney Int 1990; 3»; 1177-1180.
4. Gahow PA, Johnson AM, Kaeliny WD et al. Factors affecting the progression of renal disease in autosomal- dominant polycystic kidney disease. Kidney Int 1992; 41: 1311-1319.
5. I'ick CiM, Johnson AM, Hammond WS, Gahow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; % 2048-2056.
6. to) DD, Shaffer KM, Johnson AM, Kimlierling WJ, Dobin A. Gahow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2032-2036.
7. Gralıaııı I'C, Lindop GBM. The Linatomy of the renin-secre-ting cell in adult polycystic kidney disease. Kidney Int 1988; 33: 10B4-1O9O.
8. Chapman AB. Johnson A, Gahow PA, Schrier KW. The renin-angicrtensin-aldosterone system and autosomal dominant polycyclk' kidney disease. N Engl J Med 1990; 323: 1091¬1096.
9. Harrap SB, Da vies DL. Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991; 40; 501-508.
10. Cerasola G, Vecchi ML, Mule G el al. Sympathetic activity and blood pressure pattern in autosomal dominant polycyctic kidney disease hypertensives. Am [ Nephrol 1998; 18: 391¬398.
j 11. Klein IHHT, LigtenbergG, Oey PL. Koomans MA, Blankest ijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433¬12. Hocher B, Zan R, Schwarz A et al. Renai endothelin system in polycyctic kidney disease. J Am Soc Nephrol 1998; 9: 1169¬1177.
13- Giusti R, Neri M. Angclini D et al. Plasma concentration of endothelin and arterial pressure in patients with ADPKI). Contrib Nephrol 1995: 113: 118-121. İ 14. Wang D, iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
15. Kocaman O, Otla/ H, Yekeler E et al. Endothelial dysfunction and increased carotid intima-nıedia thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43:854-860.
16. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-2157.
17. Namli S, Oflaz H, Turgut F et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2004; 15: 219A.
18. Oflaz H, Alisir S, Buyukaydin B et al, Biventricular diastolic dysfunction in patients with autosomal dominant polycystic kidney disease. Kidney Int 2005; 68: 2244-2249.
i
19. Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990; 259; F768-F777.
20. Ruiz-Ortega M. Fgido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52: 1497-1510.
21. Chapman AB. Johnson AM, Rainguet S, Hossaek K, Gahow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycyctic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297.
i
22. Klahr S, Levey AS, Beck GJ et al., for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884. 23- Franz KA, Reubi FC. Rate of functional deterioration in polycystic kidney disease. Kidney lni 1983; 23: 526-529.
24. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycyclic kidney disease. AmJ Kidney Dis 2000; 35: 427-432.
25. Chapman AB, Johnson AM, Gahow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1.349¬1354.
26. Ecder T, Edelstein CL, Eick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycyctic kidney disease. Am J Nephrol 2001; 21: 98-103
[ 27. Nutahara K, Higashihara E, Horie S et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005; 99:cl8-c23. 28, Ecder T, Edelstein CL, Chapman AB et al. Reversal of lefl
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
25
0 Hypertension and Cardiovascular Problems in Autosomal Dominant Polycystic Kidney Disease
ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycyctic kidney disease. Nephrol Dial Transplant 1999; 14: 1113-1116
29. Schrier R. McFann K. Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease; Results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13: 1733-1739.
30. Schrier RW. McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63: 67H-685.
31. Ecder T, Edelstein CL, Fick-Brosnahan GM el al. Progress in blood pressure control in autosomal dominant polycystic kidney disease. AmJ Kidney Dis 2000; 36: 266-271.
32. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of flight Blood Pressure. Hypertension 2003; 42: 1206-1252.

Thank you for copying data from http://www.arastirmax.com